Valion Bio names Thomas Jensen board chair
ALLR•Valion Bio named Thomas H. Jensen board chair to steer development of Entolimod for acute radiation syndrome. Jensen is CEO and a director of Nasdaq-listed Allarity Therapeutics and has more than 20 years of biotech and oncology experience.
1. Jensen takes chair role
Valion Bio named Thomas H. Jensen as board chair to steer development of Entolimod for acute radiation syndrome. Jensen is CEO and a director of Allarity Therapeutics and has more than 20 years of biotech and oncology experience.
2. Allarity leadership experience
At Allarity, Jensen led a strategic refocus around lead asset stenoparib, streamlined operations, cut costs and advanced a Phase 2 ovarian cancer program.
